| Alirocumab and cardiovascular outcomes after acute coronary syndrome GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ... New England Journal of Medicine 379 (22), 2097-2107, 2018 | 3485 | 2018 |
| Efficacy and safety of alirocumab in reducing lipids and cardiovascular events JG Robinson, M Farnier, M Krempf, J Bergeron, G Luc, M Averna, ... New England Journal of Medicine 372 (16), 1489-1499, 2015 | 2595 | 2015 |
| Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes RR Holman, MA Bethel, RJ Mentz, VP Thompson, Y Lokhnygina, JB Buse, ... New England Journal of Medicine 377 (13), 1228-1239, 2017 | 2193 | 2017 |
| Sotagliflozin in patients with diabetes and recent worsening heart failure DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter, DK McGuire, ... New England journal of medicine 384 (2), 117-128, 2021 | 1750 | 2021 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1558 | 2018 |
| Vericiguat in patients with heart failure and reduced ejection fraction PW Armstrong, B Pieske, KJ Anstrom, J Ezekowitz, AF Hernandez, ... New England Journal of Medicine 382 (20), 1883-1893, 2020 | 1265 | 2020 |
| Semaglutide and cardiovascular outcomes in obesity without diabetes AM Lincoff, K Brown-Frandsen, HM Colhoun, J Deanfield, SS Emerson, ... New England Journal of Medicine 389 (24), 2221-2232, 2023 | 1145 | 2023 |
| Sotagliflozin in patients with diabetes and chronic kidney disease DL Bhatt, M Szarek, B Pitt, CP Cannon, LA Leiter, DK McGuire, JB Lewis, ... New England Journal of Medicine 384 (2), 129-139, 2021 | 1072 | 2021 |
| Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain X Duan, JH Chang, S Ge, RL Faulkner, JY Kim, Y Kitabatake, X Liu, ... Cell 130 (6), 1146-1158, 2007 | 752 | 2007 |
| Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure JR Teerlink, R Diaz, GM Felker, JJV McMurray, M Metra, SD Solomon, ... New England Journal of Medicine 384 (2), 105-116, 2021 | 614 | 2021 |
| Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial GG Schwartz, L Bessac, LG Berdan, DL Bhatt, V Bittner, R Diaz, ... American heart journal 168 (5), 682-689. e1, 2014 | 583 | 2014 |
| Signaling networks: the origins of cellular multitasking JD Jordan, EM Landau, R Iyengar Cell 103 (2), 193-200, 2000 | 580 | 2000 |
| Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes HC Gerstein, N Sattar, J Rosenstock, C Ramasundarahettige, R Pratley, ... New England journal of medicine 385 (10), 896-907, 2021 | 577 | 2021 |
| Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial PM Moriarty, PD Thompson, CP Cannon, JR Guyton, J Bergeron, FJ Zieve, ... Journal of clinical lipidology 9 (6), 758-769, 2015 | 568 | 2015 |
| Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study JJ Bazarian, P Biberthaler, RD Welch, LM Lewis, P Barzo, V Bogner-Flatz, ... The Lancet Neurology 17 (9), 782-789, 2018 | 529 | 2018 |
| Extended thromboprophylaxis with betrixaban in acutely ill medical patients AT Cohen, RA Harrington, SZ Goldhaber, RD Hull, BL Wiens, A Gold, ... New England Journal of Medicine 375 (6), 534-544, 2016 | 523 | 2016 |
| Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY … CP Cannon, B Cariou, D Blom, JM McKenney, C Lorenzato, R Pordy, ... European heart journal 36 (19), 1186-1194, 2015 | 515 | 2015 |
| Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial EC Haley Jr, JLP Thompson, JC Grotta, PD Lyden, TG Hemmen, ... Stroke 41 (4), 707-711, 2010 | 325 | 2010 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 293 | 2019 |
| Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double … JP Piccini, V Caso, SJ Connolly, KAA Fox, J Oldgren, WS Jones, ... The lancet 399 (10333), 1383-1390, 2022 | 253 | 2022 |
Renato D. LopesProfessor afiliado da EPM/UNIFESPEmail verificata su bcri.org.br
